Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET
Company Participants
Todd Tushla - VP, IR
Kevin Gorman - CEO
Matt Abernethy - CFO
Eric Benevich - Chief Commercial Officer
Eiry Roberts - Chief Medical Officer
Kyle Gano - Chief Business Development & Strategy Officer
Conference Call Participants
Philip Nadeau - TD Cowen
Paul Matteis - Stifel
Tazeen Ahmad - Bank of America
Anupam Rama - JPMorgan
Akash Tewari - Jefferies
Jay Olson - Oppenheimer
Cameron Bradshaw - Goldman Sachs
Brian Skorney - Baird
Mohit Bansal - Wells Fargo
Marc Goodman - Leerink
Carter Gould - Barclays
Myles Minter - William Blair
Cory Kasimov - Evercore ISI
Laura Chico - Wedbush Securities
Operator
Good day everyone and welcome to today's Neurocrine Biosciences' reports Second Quarter Results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions]
It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla. Please go ahead.
Todd Tushla
Thank you, Chloe. Welcome to Neurocrine Biosciences' second quarter 2024 earnings call. With me are Kevin Gorman, our current Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eiry Roberts, Chief Medical Officer; Eric Benevich, Chief Commercial Officer; and Kyle Gano, Chief Business Development and Strategy Officer, who, on October 14, will become Neurocrine's next CEO. So, yes, this will be Kevin's last earnings call, and he plans to share a few closing thoughts following Q&A.
Before we begin, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings.
With that, I hand the call to Kevin.
Kevin Gorman
Thank you, Todd. Yes, I wish they would have told me. I have closing thoughts today, but. Good morning, everyone. We have a lot to go over this morning, but what I'd first like to start out with is a statement that we have no information to share on either Luvadaxistat or NBI-'568 or M4 agonist. Both trials remain blinded, and neither database is locked.
Now, this has been an excellent quarter. I know you probably get tired of me hearing me say this. I never do. We have better than 30% year-over-year growth for INININGREZZA. We've had an approval of the INININGREZZA SPRINKLE priority review for Crinecerfont. Compelling Phase 2 data for our AMPA modulator and major depressive disorder, multiple new compounds entering the clinic, and best of all, the company will finally be rid of me.